Hong Kong stock abnormal movement | Sinopharm Holding (02096.HK) rises over 7% as FGFR2b targeted ADC completes Phase I clinical trial first patient dosing. Senoxin's recent sales volume significantly increased.

According to the "Zhixin Finance" app, Sinovac Biotech (02096.HK) has risen by more than 7%, with a increase of 7.13% as of the time of publication, reaching 10.52 Hong Kong dollars, with a trading volume of 60.9166 million Hong Kong dollars.